Consensus Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Equities

600276

CNE0000014W7

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 2026-01-19			5-day change	1st Jan Change
61.12 ^CNY	-1.32%		-4.17%	+2.60%

Jan. 12	Hengrui Pharma Unit Secures Approval to Conduct Clinical Trial for Hypertension Drug	MT
Jan. 12	Hengrui Pharma's Cancer Drug Obtains China Breakthrough Therapy Designation	MT

Evolution of the Average Target: Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Evolution of the Target Price: Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Changes in Analyst Recommendations: Jiangsu Hengrui Pharmaceuticals Co.,Ltd

7e.gdIGOTnojxjMSMO3taC43HQmzgl7boBcbOZpcln_FZc.yoZjYV2h9i6GJ6jo58vftwBPgHwSD9A3KL4nOQizIfO2hFRbWpDaLPgiqA~79ee7316b7474d44bca0459eaf75189c

Analysts' recommendations: Jiangsu Hengrui Pharmaceuticals Co.,Ltd

25-09-08	Nomura Adjusts Jiangsu Hengrui Pharmaceuticals' Price Target to 78.21 Yuan From 66.66 Yuan, Keeps at Buy	MT
25-09-08	Nomura Adjusts Jiangsu Hengrui Pharmaceuticals' Price Target to HK$94.54 From HK$80.57, Keeps at Buy	MT
25-08-22	Jefferies Adjusts Jiangsu Hengrui Medicine's Price Target to 86 Yuan From 80 Yuan, Keeps at Buy	MT
25-07-29	Nomura Upgrades Jiangsu Hengrui Medicine to Buy From Neutral, Adjusts Price Target to 66.66 Yuan From 59.15 Yuan	MT
25-07-29	Nomura Upgrades Jiangsu Hengrui Pharmaceuticals to Buy From Neutral, Adjusts Price Target to HK$80.57 From HK$71.50	MT
25-07-17	Nomura Starts Jiangsu Hengrui Pharmaceuticals at Neutral With HK$71.50 Price Target	MT
25-07-17	Nomura Adjusts Jiangsu Hengrui Medicine's Price Target to 59.15 Yuan From 53.45 Yuan, Keeps at Neutral	MT
25-04-03	Nomura Adjusts Jiangsu Hengrui Medicine's Price Target to 80 Yuan From 60 Yuan, Keeps at Buy	MT
25-03-31	Nomura Adjusts Jiangsu Hengrui Medicine's Price Target to 53.45 Yuan From 51.31 Yuan, Keeps at Neutral	MT
25-02-26	Nomura Adjusts Jiangsu Hengrui Medicine's Price Target to 51.31 Yuan From 50.17 Yuan, Keeps at Neutral	MT
25-01-13	Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics Report Positive Topline Data from 8 Mg Dose of Phase 2 Obesity Trial of GLP-1/GIP Receptor Dual Agonist HRS9531	CI
24-11-27	SPDB International HK Starts Jiangsu Hengrui Pharmaceuticals at Buy with 61 Yuan Price Target	MT
24-10-22	Nomura Adjusts Jiangsu Hengrui Medicine's Price Target to 50.17 Yuan From 48.32 Yuan, Keeps at Neutral	MT
24-07-23	Nomura Adjusts Jiangsu Hengrui Medicine's Price Target to 48.32 Yuan From 51.12 Yuan, Keeps at Neutral	MT
24-03-15	Nomura Adjusts Jiangsu Hengrui Medicine’s Price Target to 51.12 Yuan From 49.24 Yuan, Keeps at Neutral	MT
23-10-17	Nomura Adjusts Jiangsu Hengrui Medicine's Price Target to 49.24 Yuan From 50.19 Yuan, Keeps at Neutral	MT
23-07-25	Nomura Adjusts Jiangsu Hengrui Medicine's Price Target to 50.19 Yuan From 46.30 Yuan, Keeps at Neutral	MT
23-04-24	Nomura Adjusts Jiangsu Hengrui Pharmaceuticals' Price Target to 46.30 Yuan From 41.29 Yuan, Keeps at Neutral	MT
23-03-09	Nomura Adjusts Jiangsu Hengrui Medicine's Price Target to 41.29 Yuan From 38.29 Yuan, Keeps at Neutral	MT
22-08-22	Nomura Adjusts Jiangsu Hengrui Pharmaceuticals' Price Target to 34.13 Yuan From 31.71 Yuan, Keeps at Neutral	MT
22-04-25	Nomura Adjusts Jiangsu Hengrui Pharmaceuticals' Price Target to 31.71 Yuan From 55.66 Yuan, Keeps at Neutral	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	JIANGSU HENGRUI PHARMACEUTICALS CO.,LTD					+33.78%
	ELI LILLY AND COMPANY					+6.97%
	JOHNSON & JOHNSON					-3.05%
	ABBVIE INC.					+14.32%
	ROCHE HOLDING AG					-1.9%
	ASTRAZENECA PLC					+8.47%
	NOVARTIS AG					-3.4%
	MERCK & CO., INC.					+4.27%
	NOVO NORDISK A/S					+3.11%
	AMGEN INC.					+0.36%
	Average					+6.29%
	Weighted average by Cap.					+4.27%